In this study, a tumor-targeting aptamer was coupled to a DNA Td to form the Apt-Td, which not only had a significantly higher drug-loading capacity (25-fold) compared to a free MUC1 aptamer (Figure 4), but also selectively delivered the drug to MUC1-positive cancer cells. The gene discussed is MUC1; the disease is neoplasm.